返回资讯中心
外部精选
出海观察
#全球市场#中国出海#News Feed

CataX AI 获启明创投4000万元种子轮融资,将AI智能体引入临床药物开发

来源标题:CataX AI raises RMB 40 million to bring AI agents into clinical drug development

CataX AI 完成4000万元人民币种子轮融资,由启明创投独家投资,该公司也由启明创投孵化。这家上海公司计划引进或共同开发处于临床前或早期临床阶段的候选药物,并推进至临床概念验证阶段,其“Clinical-of-One”模式由临床负责人借助AI智能体审阅研究、起草文件和数据处理。

动点科技 TechNodeTechNode Feed2026/11/16 · 昨天2 分钟阅读中文

以下正文同步自 动点科技 TechNode,版权归原站所有,已转换为易读排版。

Shanghai-based CataX AI has raised RMB 40 million in a seed round from Qiming Venture Partners, which incubated the startup and was the sole investor. CataX AI plans to license or co-develop drug candidates at the preclinical or early clinical stage and advance them through clinical proof of concept. The company calls its operating model “Clinical-of-One.” A clinical lead oversees each program with support from specialists and AI agents that review research, draft documents and process data. Human experts make key decisions, and the company aims to reuse what it learns across programs. Founder and CEO Wang Zilong has a background in clinical medicine and AI research at Microsoft Research Asia, while co-founder Jiang Zhemin has more than 15 years of clinical development experience. [TechNode reporting]

正文由 探How 从来源站点 RSS 同步,内容未经改写;遇到排版缺失或需要图片、视频时请以原文为准。

打开原文
去社区讨论 →